Clinical Trial Search

Primary: The Prevalence of Superficial and Cutaneous Fungal Infections Among Drug and Non-Drug Users — 73; 62 participants

Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants

Primary: Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14 — 60.5; 71.0 percentage of participants

Primary: Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects — 2182; 2 Test site

Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site

Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates

Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants

Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…

Primary: Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose — 138262.2; 15890.1; 68634.2; 17213.9 h*pg/mL

Primary: Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO) — 19 Participants

Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale

Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site

Primary: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) — 89; 90…

Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants

Primary: Number of Participants With Local Tolerability Reactions by Severity — 54; 0; 1; 0 Participants

Primary: Percentage of Subjects — 25.3; 2.8 percentage of subjects with complete cur — p=0.025

Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants

Primary: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia (Fungal Cause of Tinea Versicolor) — 2; 4; 5; 1 Participants — p=0.2

Primary: Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a…

Primary: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure — 96; 81 Participants

Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26

Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants

Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…

Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale

Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet

Primary: Complete Cure — 63; 81; 19; 2 Participants

Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants

Primary: The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor — 7; 4 participants

Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants

Primary: Measurement of Circulating Plasma Levels of Luliconazole in Participants Who Had Tinea Pedis: Maximum Observed Plasma Concentration (Cmax) of Luliconazole — 3.27…